Objective Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enoughblood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swellingand tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate HeartFailure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% oftotal healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF,whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliestindicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV duringpatient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimallyinvasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: viainductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit whichsynchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/redcolor code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manageglucose levels in diabetes. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicinecardiologymedical and health sciencesmedical biotechnologyimplantsmedical and health sciencesclinical medicineanaesthesiology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator VECTORIOUS MEDICAL TECHNOLOGIES LTD Net EU contribution € 1 834 802,38 Address RAUL WALLENBERG 24 TEL AVIV JAFFA Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 621 146,25
